Medtronic plc, a leader in healthcare technology, has announced the expansion of CE Mark indications for its Prevail™ paclitaxel-coated PTCA balloon catheter. This approval allows for a broader range of treatments for coronary artery disease, including complex bifurcation lesions, multivessel disease, acute coronary syndrome, and diabetes. The expanded indications follow the Prevail DCB's strong performance in clinical trials, demonstrating low event rates and effectiveness in treating complex coronary lesions. This development enables Medtronic to better support physicians in providing top-tier care to patients with diverse and complex needs.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.